The German company Stratec is one of the world’s leading providers of automation solutions for in-vitro diagnostics and life science companies. It provides fully automated analyzer systems, software and smart consumables. On this, Stratec covers virtually the entire value chain for the specification, design, manufacture and approval of complex analyzer system solutions.
As a leading OEM player for automation solutions in the fields of clinical diagnostics and biotechnology, Stratec develops its products on the basis of its own patented technologies. In this way, Stratec’s partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world.
In the second quarter of 2021, STRATEC further increased the strong growth momentum already seen at the beginning of the year and posted new record levels of sales and earnings. For the first half of 2021, the company can report constant-currency sales growth of 36.0% and an 87.1% increase in its adjusted EBIT. This strong growth continued to be driven by high demand for diagnostics products relating to the COVID-19 pandemic.
The future growth drivers include an aging world population, a rising prevalence of chronic diseases, an expansion in healthcare systems in emerging markets and a new technologies broadening scope of non-invasive prenatal testing. For the first six months of the 2021 financial year, Stratec reported double-digit sales and earnings growth rates in all three of its segments (Instrumentation, Diatron, Smart Consumables).
As a result of the strong sales growth, the Annual General Meeting approved a further record dividend of € 0.90 per share. This marks the seventeenth consecutive increase since payment of the first dividend in 2004. Shares in the company are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.